Innovative Health Initiative (IHI)

Overview
The Innovative Health Initiative (IHI) will build on the successes of, and lessons learnt from, Innovative Medicines Initiative (IMI). It will contribute to a number of European policies, most notably Europe’s Beating Cancer Plan, the new Industrial Strategy for Europe and the Pharmaceutical Strategy for Europe.

Goal
The goal of IHI is to help create an EU-wide health research and innovation ecosystem that facilitates the translation of scientific knowledge into tangible innovations. These innovations should be safe, effective, people-centred and cost-effective, and cover prevention, diagnostics, treatment and disease management.

Eligibility
Participants from Switzerland will be included in the project as an “Associated Partner” (AP) from a non-associated third country for the 2022 calls. Such Associated Partners do not count towards the minimum number of participants. If the proposal is successful, in principle, the cost of the CH entity will be reimbursed by the Swiss State Secretariat for Education, Research and Innovation. Associated Partners cannot coordinate a project. However, they can act as Work Package Leaders.

Project Partners
As is the case in IMI, the ‘public’ partner is the European Union, represented by the European Commission (EC). The IHI industry partners are COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe.
In addition, organisations that want to support specific areas of research without becoming full members of IHI can apply to become ‘contributing partners’.

Financial Support
The total budget proposed for IHI is EUR 2.4 billion, half of it contributed by the EC.

Further Details/ Contact European Partnership
Dr Sasha Hugentobler
Dr Nicole Wyss
National Contact Points Health
health@euresearch.ch


Swiss State Secretariat for Education, Research and Innovation: www.horizon-europe.ch